DAFTAR PUSTAKA
Atkinson, G. P., Nozell, S. E., & Benveniste, E. T. N. (2010). NF-κB and STAT3 signaling in glioma: targets for future therapies. Expert Review of Neurotherapeutics, 10(4), 575–586. http://doi.org/10.1586/ern.10.21
Colen, C. B., & Allcut, E. (2012). Quality of life and outcomes in glioblastoma management.
Neurosurgery Clinics of North America, 23(3), 507–513. http://doi.org/10.1016/j.nec.2012.04.010
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., et al. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & Development, 21(21), 2683–2710. http://doi.org/10.1101/gad.1596707
Hayasshi,S., Yamamoto, M., Ueno, Y., Ikeda, K., Ohsima, K., Soma, G.-I., & Fukushima, T. (2001). Expression of Nuclear Factor-κB, Tumor Necrosis Factor Receptor Type 1, and c-Myc in Human Astrocytomas. Neurologia Medico-Chirurgica, 41(4), 187–195. http://doi.org/10.2176/nmc.41.187
Hentschel, S. J., & Lang, F. F. (2003). Current Surgical Management of Glioblastoma. The Cancer Journal, 9(2).
Ishkanian, S., Laperriere, N. J., Xu, W., et al. (2011). Upfront observation versus radiation for adult pilocytic astrocytoma. Cancer, 117(17): 4070-9.
Kim, Y.-H., & Kim, C.-Y. (2012). Current surgical management of insular gliomas.
Neurosurgery Clinics of North America, 23(2), 199–206– vii. http://doi.org/10.1016/j.nec.2012.01.010
Korkolopoulou, P., Levidou, G., Saetta, A. A., El-Habr, E., Eftichiadis, C., Demenagas, P., et al. (2008). Expression of nuclear factor-κB in human astrocytomas: relation to pIκBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival.
Human Pathology, 39(8), 1143–1152. http://doi.org/10.1016/j.humpath.2008.01.020
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., et al. (2007). The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 114(2), 97–109. http://doi.org/10.1007/s00401-007-0243-4
McLendon, R., Friedman, A., Bigner, D., Van Meir, E. G., Brat, D. J., M Mastrogianakis, G., et al. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068. http://doi.org/10.1038/nature07385
Nagasawa, D. T., Chow, F., Yew, A., Kim, W., Cremer, N., & Yang, I. (2012). Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme. Neurosurgery Clinics of North America, 23(2), 307–322. http://doi.org/10.1016/j.nec.2012.01.007
Ohgaki, H., & Kleihues, P. (2013). The definition of primary and secondary glioblastoma.
Clinical Cancer Research, 19(4), 764–772. http://doi.org/10.1158/1078-0432.CCR-12-3002
Omuro, A. (2013). Glioblastoma and Other Malignant Gliomas. Jama, 310(17), 1842–9. http://doi.org/10.1001/jama.2013.280319
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., et al. (2013). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro-Oncology, 15(suppl 2), ii1–ii56. http://doi.org/10.1093/neuonc/not151
Puliyappadamba, V. T., Hatanpaa, K. J., Chakraborty, S., & Habib, A. A. (2014). The role of NF-κB in the pathogenesis of glioma. Molecular & Cellular Oncology, 1(3), e963478. http://doi.org/10.4161/23723548.2014.963478
Reardon, D. A. (2006). Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. The Oncologist, 11(2), 152–164.
http://doi.org/10.1634/theoncologist.11-2-152
Taw, B. B. T., Gorgulho, A. A., Selch, M. T., & De Salles, A. A. F. (2012). Radiation options for high-grade gliomas. Neurosurgery Clinics of North America, 23(2), 259–67– viii. http://doi.org/10.1016/j.nec.2012.01.003
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al. (2010). Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell, 17(1), 98–110. http://doi.org/10.1016/j.ccr.2009.12.020
